Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...

Investors with substantial losses have the opportunity (until August 25, 2025) to move the court for appointment as Lead Plaintiff. Shareholder rights firm Hagens Berman is investigating the legal ...

Recent health-related developments include Britain's decisions on the bioethanol industry, Berkshire Hathaway's new stake in ...

US stocks opened mixed Friday as strong retail sales data offset hotter wholesale inflation, with UnitedHealth surging on ...

The disclosure in a filing Thursday gave a much-needed boost to the beleaguered health insurance giant, which saw shares jump as much as 9.6% in post-market trading. In other news: Nike co-founder ...

Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...

Telehealth and wellness platform Hims & Hers Health ($HIMS) recently disappointed investors with its mixed second-quarter ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

Investing.com -- Hims & Hers Health (NYSE:HIMS) stock dropped 2.6% on Friday following reports that the Federal Trade Commission has been investigating the telehealth company's business practices for ...

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than ...

The US health sector is bustling with activity. Key developments include an FTC investigation into Hims & Hers' practices, ...